These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18555553)

  • 1. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
    Overbeck K; Genné D; Golay A; Negro F;
    J Hepatol; 2008 Aug; 49(2):295-8. PubMed ID: 18555553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Serfaty L; Fartoux L; Poupon R
    J Hepatol; 2009 Jun; 50(6):1269-71. PubMed ID: 19395115
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19(12):S79-81. PubMed ID: 15641210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin, hepatitis C, and insulin resistance: sufficient evidence?
    Yilmaz Y; Yonal O; Imeryuz N
    Hepatology; 2009 Dec; 50(6):2054-5; author reply 2055. PubMed ID: 19937685
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful antiviral and antituberculosis treatment with pegylated interferon-alfa and ribavirin in a chronic hepatitis C patient with pulmonary tuberculosis.
    Tsai MC; Lin MC; Hung CH
    J Formos Med Assoc; 2009 Sep; 108(9):746-50. PubMed ID: 19773215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of PEG-interferon alfa-2a plus ribavirin as treatment for chronic HCV hepatitis in a child cured of ALL.
    Lo Nigro L; La Spina M; Mirabile E; Pisana P; Schilirò G; Guardo P
    Pediatr Blood Cancer; 2004 Aug; 43(2):185. PubMed ID: 15236293
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
    Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
    J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Difficult-to-treat patients with chronic hepatitis C].
    Zeuzem S
    Praxis (Bern 1994); 2006 Sep; 95(38):1459-64. PubMed ID: 17058596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Retreatment strategies for the patients with HCV infection].
    Pawłowska M
    Przegl Epidemiol; 2005; 59(2):591-4. PubMed ID: 16190570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G; Pal S; Nayyar I; Dey S
    Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
    Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
    Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
    McHutchison J; Sulkowski M
    J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.